Noriko Iwaki

Chuo, 1040045, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

Effectiveness of anti-CD19 CAR T-cell therapy for high-grade B-cell lymphoma in Japan: a single-institution analysis.

Effectiveness of anti-CD19 CAR T-cell therapy for high-grade B-cell lymphoma in Japan: a single-institution analysis.

Journal: International journal of clinical oncology

Published: May 02, 2026

Body Mass Index and Outcomes after CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Nationwide Registry Study.

Body Mass Index and Outcomes after CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Nationwide Registry Study.

Journal: Transplantation and cellular therapy

Published: April 27, 2026

Association between CD79B expression and polatuzumab vedotin efficacy, and therapy-induced changes in CD79B expression in diffuse large B-cell lymphoma.

Association between CD79B expression and polatuzumab vedotin efficacy, and therapy-induced changes in CD79B expression in diffuse large B-cell lymphoma.

Journal: Virchows Archiv : an international journal of pathology

Published: March 27, 2026

T-cell fitness, metabolic tumor volume, and serum LDH levels are associated with response to axicabtagene ciloleucel.

T-cell fitness, metabolic tumor volume, and serum LDH levels are associated with response to axicabtagene ciloleucel.

Journal: International journal of hematology

Published: January 19, 2026

Real-world outcomes of chimeric antigen receptor T-cell therapy with pembrolizumab as holding and/or bridging therapy in relapsed/refractory primary mediastinal large B-cell lymphoma.

Real-world outcomes of chimeric antigen receptor T-cell therapy with pembrolizumab as holding and/or bridging therapy in relapsed/refractory primary mediastinal large B-cell lymphoma.

Journal: International journal of clinical oncology

Published: January 09, 2026

Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis.

Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis.

Journal: Blood advances

Published: December 24, 2025

Consideration of the natural history of BCL2-positive follicular lymphoma: based on tumor site, histological grade, and histological transformation rate.

Consideration of the natural history of BCL2-positive follicular lymphoma: based on tumor site, histological grade, and histological transformation rate.

Journal: Human pathology

Published: October 26, 2025

Differential Expression of CD79B, CD19, and PD-L1 in de Novo and Transformed CD20-Negative Large B-Cell Lymphomas.

Differential Expression of CD79B, CD19, and PD-L1 in de Novo and Transformed CD20-Negative Large B-Cell Lymphomas.

Journal: Hematological oncology

Published: September 29, 2025

Schizophyllum commune infection following chimeric antigen receptor T-cell therapy in a patient with lymphoma.

Schizophyllum commune infection following chimeric antigen receptor T-cell therapy in a patient with lymphoma.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: September 28, 2025

Humoral and T-cell immune responses to coronavirus disease 2019 vaccines in patients with hematological malignancies.

Humoral and T-cell immune responses to coronavirus disease 2019 vaccines in patients with hematological malignancies.

Journal: Japanese journal of clinical oncology

Published: September 03, 2025

Real-world effectiveness and safety of lisocabtagene maraleucel for relapsed/refractory large B cell lymphoma in Japan.

Real-world effectiveness and safety of lisocabtagene maraleucel for relapsed/refractory large B cell lymphoma in Japan.

Journal: International journal of clinical oncology

Published: August 31, 2025

Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.

Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.

Journal: Leukemia

Published: August 22, 2025

Showing 1-12 of 57

Last Updated: 09/26/2026